TMDX Earnings Date: Nov 5, 2026 (Estimated) — TransMedics Group, Inc.
NASDAQ · Healthcare · Medical Devices
Updated
When is TMDX's next earnings date?
TransMedics Group, Inc. (TMDX) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.30 on revenue of $178.0M.
How did TMDX do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), TransMedics Group, Inc. posted EPS of $0.44 versus the $0.52 estimate, a miss of 15.4%. Revenue was $189.9M against a $184.1M estimate. The stock's 1-day post-earnings move was -5.3%.
How much does TMDX stock move after earnings?
TMDX beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 10.8% (up or down) in the day after earnings.
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | 0.52 | 0.44 | -15.38% | $189.9M | ❌ Miss | -5.28% | +10.66% | +4.38% |
| 2026-05-05 | Q1 2026 | 0.61 | 0.30 | -50.82% | $173.9M | ❌ Miss | -23.19% | -32.66% | -24.82% |
| 2026-02-24 | Q4 2025 | 0.39 | 0.57 | +46.15% | $160.8M | ✅ Beat | -4.30% | +7.42% | -23.70% |
| 2025-10-29 | Q3 2025 | 0.36 | 0.66 | +83.33% | $143.8M | ✅ Beat | +1.09% | -7.34% | +8.93% |
| 2025-07-30 | Q2 2025 | 0.45 | 0.92 | +104.44% | $157.4M | ✅ Beat | +10.46% | +10.31% | +8.38% |
| 2025-02-27 | Q4 2024 | 0.16 | 0.19 | +18.75% | $121.6M | ✅ Beat | +5.82% | -9.47% | -4.91% |
| 2024-10-28 | Q3 2024 | 0.30 | 0.12 | -60.00% | $108.8M | ❌ Miss | -29.90% | -32.69% | -36.15% |
| 2024-07-31 | Q2 2024 | 0.21 | 0.35 | +66.67% | $114.3M | ✅ Beat | +6.50% | +2.52% | +17.14% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $189.9M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 58.5% | $111.2M | +15.7% | $74.9M | $88.2M | $96.1M | $87.7M |
| Service | 41.5% | $78.8M | +28.6% | — | $55.3M | $61.3M | $56.1M |
By region
Q2 FY23 · $3.2M total
| Segment | Share | Revenue | YoY | Q4 FY21 | Q1 FY22 | Q2 FY22 | Q3 FY22 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 87.5% | $2.8M | -84.5% | $7.2M | $13.6M | $18.1M | $23.3M |
| Other Countries | 12.5% | $403K | — | — | — | — | $2.4M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.